Video interview: Iconovo’s CEO presented the company at the LSX World Congress
Last week it was once again time for the big investor and partnering meeting focused on life science, the LSX World Congress in London.
The sixth edition…
Market analysis of Iconovo – Healthcare Direkt (only in swedish)
Market analysis of Iconovo by Siri Ladow, Analyst, Head of Commissoned Research
Danske Bank, Sweden. Healthcare Direkt.
Orest Lastow change role to CTO and Johan Wäborg hired as new CEO of Iconovo AB
Dr Orest Lastow will take on the role of CTO of Iconovo while Johan Wäborg is hired as the new CEO of Iconovo entering this role no later than April 14th…
Iconovo aims for more innovations in inhalation
Looking back on Iconovo’s 2019, the company’s investment in the new inhalation platform ICOpre and the accompanying dry power formulations stands out.…
Spray inhalers – a major climate change culprit according to a new study
Compared to dry powder inhalers, spray inhalers are a significant climate change culprit. Furthermore, many patients would make the switch to a more environmentally…
Directed share issue of 60 million SEK to finance Iconovo’s new inhalation platform
A few weeks ago, Lund-based Iconovo gave a sign of their growing confidence when they announced the biggest investment in the company’s history in the…
Iconovo AB carries out a directed share issue and raises SEK 60 million before issue costs
The Board of Directors of Iconovo AB ("Iconovo" or the “Company") has utilised the authorisation received at the AGM on 15 May 2019 and resolved on a…
PRESS RELEASE, 19 November 2019
Granted ICOres patent in Japan
The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several…
Iconovo met innovation companies at BIO-Europe
At last week’s BIO-Europe conference, BioStock caught Iconovo’s Roger Lassing, VP of Business Development, between a series of interesting meetings.
We…
Iconovo’s new collaboration aims to optimise current inhalation products
British CrystecPharma begins a collaboration with the Swedish inhaler developer Iconovo with the aim of formulating new innovative compounds for use in…
PRESS RELEASE, 5 November 2019
Iconovo and CrystecPharma to collaborate in development of innovative inhaler products
Iconovo today announced that it signed a Letter of Understanding…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se